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ABSTRACT
Influenza virus neuraminidase (NA) is an interesting target of small-molecule antiviral drugs. We isolated a set of H5N1 NA-
specific single-domain antibodies (N1-VHHm) and evaluated their in vitro and in vivo antiviral potential. Two of them inhib-
ited the NA activity and in vitro replication of clade 1 and 2 H5N1 viruses. We then generated bivalent derivatives of N1-VHHm
by twomethods. First, we made N1-VHHb by genetically joining two N1-VHHmmoieties with a flexible linker. Second, bivalent
N1-VHH-Fc proteins were obtained by genetic fusion of the N1-VHHmmoiety with the crystallizable region of mouse IgG2a
(Fc). The in vitro antiviral potency against H5N1 of both bivalent N1-VHHb formats was 30- to 240-fold higher than that of their
monovalent counterparts, with 50% inhibitory concentrations in the low nanomolar range. Moreover, single-dose prophylactic
treatment with bivalent N1-VHHb or N1-VHH-Fc protected BALB/c mice against a lethal challenge with H5N1 virus, including
an oseltamivir-resistant H5N1 variant. Surprisingly, an N1-VHH-Fc fusion without in vitroNA-inhibitory or antiviral activity
also protected mice against an H5N1 challenge. Virus escape selection experiments indicated that one amino acid residue close to
the catalytic site is required for N1-VHHm binding. We conclude that single-domain antibodies directed against influenza virus
NA protect against H5N1 virus infection, and when engineered with a conventional Fc domain, they can do so in the absence of
detectable NA-inhibitory activity.
IMPORTANCE
Highly pathogenic H5N1 viruses are a zoonotic threat. Outbreaks of avian influenza caused by these viruses occur in many parts
of the world and are associated with tremendous economic loss, and these viruses can cause very severe disease in humans. In
such cases, small-molecule inhibitors of the viral NA are among the few treatment options for patients. However, treatment with
such drugs often results in the emergence of resistant viruses. Here we show that single-domain antibody fragments that are spe-
cific for NA can bind and inhibit H5N1 viruses in vitro and can protect laboratory mice against a challenge with an H5N1 virus,
including an oseltamivir-resistant virus. In addition, plant-produced VHH fused to a conventional Fc domain can protect in
vivo even in the absence of NA-inhibitory activity. Thus, NA of influenza virus can be effectively targeted by single-domain anti-
body fragments, which are amenable to further engineering.
Zoonotic influenza A virus infections are a persistent threatbecause of their pandemic potential. In particular, highly
pathogenic avian influenza viruses (HPAIV) of the H5N1, H7N1,
andH7N7 subtypes occasionally cross the species barrier between
domesticated birds and humans. These viruses could become
transmissible between humans through reassortment with circu-
lating swine or human influenza viruses or by gradually accumu-
latingmutations (1, 2). In the last decade, zoonotic outbreaks have
had a major effect on public health. HPAIV H5N1 (3), the swine
influenza (H1N1) outbreak in 2009 (4), and more recently, hu-
man infections withH7N9 in southern Asia (5) illustrate our poor
preparedness for pandemic influenza (6). HPAIVH5N1 infection
in humans has a confirmed case fatality rate of approximately
60%. The high pathogenicity of HPAIV H5N1 in humans can be
attributed to a high replication rate and a broad cellular tropism
that can lead to systemic virus spread. In addition, deregulated
induction of proinflammatory cytokines and chemokines (“cyto-
kine storm”) is associated with severe HPAIV H5N1 infections
and can result in a disproportionate immunological response (7).
Influenza virus neuraminidase (NA) is a homotetrameric type
IImembrane glycoprotein with sialidase activity. TheNA catalytic
site is located at the top of each monomer, opposite the tetramer
interface. NA plays an essential role in the spread of influenza
viruses by cleaving sialic acids from the host cell receptors and
from virions. NA activity also contributes to virus entry by cleav-
ing decoy receptors present in mucins that line the layer of respi-
ratory epithelial cells (8). Immunologically, NA is the second ma-
jor humoral antigenic determinant (after hemagglutinin [HA])
and is subject to antigenic drift and occasional shift. In addition,
experimental influenza vaccines supplemented with NA have im-
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proved efficacy (9–11). NA is also a codeterminant of influenza A
virus (IAV) pathogenicity (12–14) and is involved in limiting IAV
superinfections and reassortment (15). Decreased NA activity has
been correlated with H5N1 adaptation to the human airway epi-
thelium (16), and antibodies (Abs) against NA contribute to pro-
tection against an H5N1 virus challenge in a mouse model (17).
HA, the other major antigen, and NA cooperate in a tightly
controlledway. For example, the fitness ofmutant IAV lackingNA
activity can be rescued by the selection of HA mutants with a
decreased affinity for receptors containing sialic acid (18–20).
These data demonstrate the importance of NA during IAV infec-
tion, so targeting of NA is a rational strategy. Indeed, three li-
censed influenza antivirals, oseltamivir, zanamivir, and peramivir,
target NA. Influenza viruses that are resistant to oseltamivir fre-
quently emerge in humans. In addition, NA-specific Abs protect
mice and serum anti-NA Abs are associated with resistance to an
IAV challenge in humans (21).
Effective prevention and treatment strategies are needed to
control H5N1 infections, and antivirals based on single-domain
Ab-based technology have been described as promising (22). Nat-
urally occurring single-heavy-chain Abs have been found in
sharks and camelids (23, 24). Unlike conventional Abs that are
typically composed of light and heavy polypeptide chains that to-
gether determine epitope specificity, these natural single-chain
Abs are composed of heavy chains only, and hence, their epitope
specificity is confined to a single domain (so-called VHH, variable
domain of heavy chain). Single-domain Ab fragments derived
from camelids are highly specific, robust, easy to produce, and
flexible. Hence, they are often used as novel therapeutics formany
diseases (25, 26). VHHs usually have extended Ab loop structures
and can interact with cognate antigenswith affinitiesmatching the
best affinities of conventional Abs (27–29). In addition, VHHs
that potently inhibit enzymes have been described (30, 31), and
they have been used to stabilize membrane proteins in order to
determine crystal structure (32). The VHH tends to target con-
cave-shaped epitopes, in contrast to the planar epitopes that are
typically recognized by “classical” light- and heavy-chain Abs
(33). In addition, several examples of VHHs with potent antiviral
activity have been reported (34–36).Wehave previously described
an HA-specific H5N1-neutralizing VHH (35), andmore recently,
anH5N2-neutralizing VHHwas reported (37).Moreover, a VHH
directed against the influenza virus M2 protein inhibited the rep-
lication of amantadine-sensitive and -resistant viruses and pro-
tected mice against a lethal influenza virus challenge (38). Re-
cently, Harmsen et al. described a panel of NA-binding VHHs,
some of which displayed cross-subtype NA binding, but the anti-
viral potential of these VHHs was not evaluated (39).
Here, we report the isolation and characterization of a set of
H5N1 NA-binding VHHs (N1-VHHm) some of which have po-
tent NA-inhibitory activity and in vitro and in vivo antiviral activ-
ities. We also describe the production of bivalent, in-tandem N1-
VHHm formats in Escherichia coli and N1-VHHm proteins fused
to a mouse IgG2a Fc domain in seeds of transgenic Arabidopsis
plants. Further, we compared their in vitro antiviral activities
against H5N1 clade 1 (oseltamivir-sensitive and -resistant strains)
with those against clade 2 viruses, and we evaluated the N1-
VHHm-based prophylactic protection of mice against a poten-
tially lethal infection with H5N1 virus.
MATERIALS AND METHODS
Influenza viruses. H5N1 IAV strains NIBRG-14 and NIBRG-23 were
obtained from the UK National Institute for Biological Standards
and Control, a center of the Health Protection Agency. NIBRG-14
and NIBRG-23 are 2:6 reverse genetics-derived reassortants with NA and
HA segments derived from A/Vietnam/1194/2004 (H5N1) and Aturkey
Turkey2005 (H5N1), respectively, and the other six segments fromA/PR/
8/34 (H1N1) viruses. The H5N1 H274Y virus described here is a 1:1:6
reverse genetics-derived reassortant, with NA derived from A/crested ea-
gle/Belgium/01/2004 (40) carrying the H274Y mutation introduced by
site-specific mutagenesis, HA from NIBRG-14, and the remaining six ge-
nome segments from A/PR/8/34 (41). This virus was rescued by transfec-
tion of cocultured HEK-293T and MDCK cells. The supernatant from
these cells was used for endpoint dilution to obtain a clonal H5N1H274Y
virus sample that was subsequently amplified on MDCK cells, pelleted
from the cell supernatant, andmouse adapted by serial passage in BALB/c
mice. All of the HA segments of these H5N1 viruses lack the coding infor-
mation for the polybasic cleavage site. Following adaptation to BALB/c
mice, the HA and NA coding regions of mouse-adapted NIBRG-14 (NI-
BRG-14ma) and H5N1 H274Y (H5N1 H274Yma) were sequenced and
found to be identical to those of the parental viruses. Pandemic H1N1
(pH1N1) (kindly provided by Bernard Brochier, Scientific Institute of
Public Health, Brussels, Belgium) is derived from a clinical isolate of the
pH1N1 virus of 2009 and was adapted to mice by serial passage (42).
A/New Caledonia/20/99 was kindly provided by Alan Hay (Medical Re-
search Council [MRC] National Institute for Medical Research, London,
United Kingdom). Themedian tissue culture infective dose (TCID50) and
median lethal dose (LD50) of the NIBRG-14ma and H5N1 H274Yma
viruses were calculated by themethod of Reed andMuench (43). All of the
H5N1 and pH1N1 experiments described above were performed in bio-
safety level 2 rooms.
Baculovirus-based production of recombinant soluble tetrameric
NA. Soluble and enzymatically active tetramericNA (N1rec) derived from
A/crested eagle/Belgium/01/2004 (H5N1) was produced by proprietary
technology (WO 2002/074795). Briefly, the N1rec expression cassette
consisted of the secretion signal of IAV HA (ssHA, 16 residues), a te-
tramerizing variant of the leucine zipper domain of the Saccharomyces
cerevisiae GCN4 transcription factor (tGCN4, 32 residues) (44, 45), and
the extracellular part of NA derived from A/crested eagle/Belgium/01/
2004 (H5N1; amino acid residues 53 to 449) (40) (Fig. 1A). This N1rec
expression cassette was cloned into the pAcMP2 baculovirus transfer vec-
tor to produce pAcMP2n1rec. Recombinant baculovirus was generated by
cotransfection of pAcMP2n1rec and linearized DNA of Autographa cali-
fornica nuclear polyhedrosis virus (AcNPV) (BaculoGold; BD Biosci-
ences) into Sf9 insect cells (derived from Spodoptera frugiperda) with the
ESCORT IV Transfection Reagent (Sigma-Aldrich) to generate N1rec en-
coding recombinant baculovirus. Sf9 cells infected with AcNPVN1rec
were incubated at 28°C in rolling bottles in TC-100 medium (Invitrogen)
supplemented with 10% fetal calf serum and penicillin plus streptomycin.
Four days after infection, the supernatant was harvested and clarified by
centrifugation (1 h at 50,000 g).
Recombinant NA purification.All purification steps were carried out
at 4°C. Two parts (vol/vol) of n-butanol were added to three parts of
cleared, AcNPVN1rec-infected Sf9 cell supernatant, and the mixture was
shaken vigorously for 5 min. The aqueous phase, containing soluble
N1rec, was separated from the organic phase, diluted 2.5 times in 5 mM
KH2PO4 (pH 6.6), and passed through a 0.22-mfilter. The diluted aque-
ous phase was subsequently applied to an XK2670 column (GE Health-
care) packed with HA Ultrogel hydroxyapatite chromatography sorbent
(Pall) and eluted with a gradient of 5 to 400 mMKH2PO4 (pH 6.6) in 4%
butanol. Eluted fractions with high NA activity were pooled and loaded
onto a Blue Sepharose (Sigma-Aldrich) column equilibrated with 50 mM
2-(N-morpholino)ethanesulfonic acid (MES; pH 6.6) containing 5%
glycerol and 8 mM CaCl2. Bound proteins were eluted with 50 mM MES
(pH 6.6) containing 5% glycerol, 8 mMCaCl2, and 1.5MNaCl. Fractions
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with NA activity were loaded onto a HiLoad 16/60 Superdex 200 (GE
Healthcare) gel filtration column preequilibrated with 50 mM MES (pH
6.6) with 5% glycerol, 8 mM CaCl2, and 150 mM NaCl. Peak fractions
containing NA activity were pooled, aliquoted, and stored at80°C until
used. All chromatography steps were performedwith anAkta purification
station (GE Healthcare).
NAactivity assays.NAactivitywas quantifiedbymeasuring the rate of
cleavage of the fluorogenic substrate 4-MUNANA (2=-4-methylumbel-
liferyl--D-N-acetylneuraminic acid, sodium salt hydrate; Sigma-Al-
drich) into 4-methylumbelliferone. The NA activity reaction was per-
formed with 200 mM sodium acetate (NaAc)–2 mM CaCl2 with 1%
butanol and 1 mM 4-MUNANA and measured in a kinetic mode with an
excitationwavelength of 365 nmand an emissionwavelength of 450 nm in
a FLUOstar Optima. A standard curve of increasing concentrations of
soluble 4-methylumbelliferone was included to correlate the fluorescence
intensity with the molar amount of 4-methylumbelliferone. One unit of
NA activity is defined as the activity needed to generate 1 nmol of
4-methylumbelliferone/min.
Fetuin (5g/ml; Sigma-Aldrich) was used to coat Nunc 96-well plates
overnight at 4°C. Excess fetuin was washed away with phosphate-buffered
saline (PBS), and IAV dilutions (in PBS with 1 mM CaCl2 and 0.5 mM
MgCl2), with or without added single-domain Abs, were added and incu-
bated for 1 h at 37°C. The amount of desialylated fetuin was measured by
colorimetry to determine the binding of horseradish peroxidase (HRP)-
coupled peanut agglutinin (PNA; Sigma-Aldrich). The plates were
washed three times with PBS–0.1%Tween 20 and then incubated with 50
l PNA-HRP (2.5g/ml in PBS–0.05% Tween 20) at room temperature.
The plates were then washed three times with PBS, after which 50 l of
3,3=,5,5=-tetramethylbenzidine (TMB) substrate (Pharmingen BD) was
added, and absorbance at 450 nm was measured with a reference at 655
nm. In the accelerated viral inhibition assay (AVINA) (46), IAV dilutions
containing the N1-VHHm concentrations indicated were transferred to a
black 96-well plate and 75 l of 20 M 4-MUNANA was added and
incubated 1 h at 37°C. A 100-l volume of stop solution (0.1 M glycine
[pH 10.7], 25% ethanol) was then added to each well, and fluorescence
was determined. For the AVINA and fetuin substrate assays, the amounts
of IAV used were 7  105 PFU of NIBRG-14ma, 1  104 PFU of H5N1
H274Yma, and 3 104 PFU of pH1N1.
Camelid immunization, phage library construction, and panning.
An alpaca (Vicugna pacos) was injected subcutaneously with 125 g of
N1rec in the presence of incomplete Freund’s adjuvant. Injections were
administered once a week for 5 weeks. On day 39, anticoagulated blood
was collected, lymphocytes were isolatedwith aUNI-SEP density gradient
separation kit (NOVAmed), and total RNA was extracted. cDNA was
prepared with oligo(dT) primers, and the VH and VHH genes were am-
plified with primers CALL001 (GTCCTGGCTGCTCTTCTACAAGG)
and CALL002 (GGTACGTGCTGTTGAACTGTTCC). PstI and NotI re-
striction siteswere inserted into the amplified sequenceswith primersA6E
(GATGTGCAGCTGCAGGAGTCTGGRGGAGG) and 38 (GGACTAGT
GCGGCCGCTGGAGACGGTGACCTGGGT). The resulting PCR prod-
uct (550 bp) and the pHEN4 vector were digested with PstI and NotI,
ligated (47), and transformed into electrocompetent E. coli TG1 cells.
Transformants were grown in 2TY medium (supplemented with 100
g/ml ampicillin and 1% glucose) and infected with helper phage
M13K07. The resulting VHHphage display library was panned four times
with solid-phase coated N1rec.
Production and purification of monovalent NA-binding VHH (N1-
VHHm). The VHH coding sequence of the selected N1rec-binding
phages (n  13) was amplified by PCR with primers A6E and 38. The
N1rec-bindingVHHgenes obtained by PCR and the pHEN6c vector were
digested with PstI and BstEII, ligated, and transformed into E. coli WK6
cells. In the pHEN6c vector, the coding sequences of the N1rec-binding
VHH candidates were cloned downstream of an N-terminal PelB secre-
tion signal sequence and a carboxy-terminal hexahistidine tag was intro-
duced (Fig. 1B) (48). For production and purification of soluble VHH,
pHEN6c-transformed WK6 cells were grown in TB medium supple-
mented with 100 g/ml ampicillin, 2 mMCaCl2, and 0.1% glucose. After
16 h, VHH production was induced with 1 mM isopropyl--D-thiogalac-
topyranoside, and the periplasmic fraction was extracted by osmotic
shock with 0.2 M Tris (pH 8.0)–0.5 mM EDTA–0.5 M sucrose. Periplas-
mic extracts were centrifuged at 8,000 rpm and 4°C, and the supernatant
was applied to aHis Select Nickel Affinity gel (Sigma-Aldrich). After load-
ing, the column was washed with PBS and VHHs were eluted with 0.5 M
imidazole and dialyzed against PBS at 4°C. Monovalent N1rec-binding
VHH (N1-VHHm) was concentrated with a Vivaspin 5,000-kDa cutoff
filter (Vivascience). The total protein concentration was determined with
the bicinchoninic acid protein assay kit (Thermo Scientific), and endo-
toxin levels was determinedwith a commercial Limulus amebocyte lysate-
based assay (Toxinsensor Chromogenic LAL Endotoxin Assay kit; Gen-
Script Corp.). We obtained 13 recombinant N1 NA-specific VHH
proteins, which were named N1-1-VHHm to N1-13-VHHm. An irrele-
vant monovalent VHH against Arabidopsis thaliana albumin (SA-
VHHm) was used as a negative control (49). The N1-VHHm sequences
were aligned with the MegAlign software (DNAStar), and the VHH com-
plementarity-determining region 3 (CDR3) electronegativity surface po-
FIG 1 Characterization of monovalent N1-VHH candidates that bind recombinant H5N1-derived NA. (A) Soluble N1rec derived from A/crested eagle/
Belgium/01/2004 (H5N1) expressed in Sf9 cells. Diagram of the n1rec baculovirus expression cassette at the top: promoter, baculovirus basic protein promoter;
ssHA, secretion signal of HA; tGCN4, tetramerizing GCN4-derived leucine zipper; H5N1 NA, extracellular domain of NA (amino acid residues 53 to 449). The
graph at the bottom shows NA activity in the culture supernatants of different amounts of AcNPVN1rec-infected cells or mock-infected cells, with 4-MUNANA
as the substrate. RFU, relative fluorescence units. (B) Schematic representation of the expression cassettes of N1rec-binding VHH domains and derived bivalent
formats. Bacterium-produced monovalent N1-VHHm (N1-vhhm), with the amino-terminal periplasmic signal sequence (pelB), the n1-vhhm coding informa-
tion, and a carboxy-terminal hexahistidine tag (his) (top). Bacterium-produced bivalent N1-VHHb with two n1-vhhmmoieties fused by a flexible linker (llama
IgG2c hinge) and a hexahistidine tag (his) (middle). For expression in transgenic A. thaliana seeds, the N1-VHH-Fc insert was cloned into the seed-specific
expression cassette of the PphasGW vector. LB, left border of T-DNA; 3=ocs, 3= end of the octopine synthase gene; nptII, neomycin phosphotransferase II open
reading frame; Pnos, nopaline synthase gene promoter; Pphas, -phaseolin gene promoter; 5=utr, 5= untranslated region of the arc5-I gene; SS, signal sequence
of the A. thaliana 2S2 seed storage protein gene; n1-vhh-fc, coding sequence of the N1-VHH gene fused to mouse CH2 and CH3 IgG2a; KDEL, endoplasmic
reticulum retention signal; 3=arc, 3=-flanking regulatory sequences of the arc5-I gene; RB, T-DNA right border (bottom). (C) CDR3 sequences of 13 N1rec-
binding VHH candidates. VHH CDR3 is highlighted by a red dotted box. The colored histogram denotes the homology between the sequences as follows: red,
100%; orange, 60 to 80%; green, 40 to 60%; light blue, 20 to 40%; dark blue,	20%. (D) In silico prediction of the three-dimensional structure of monomeric
N1rec-binding VHHs (N1-VHHm). Structures were predicted with ESyPred3D, and diagrams were generated with DeepView software. Positive (blue) and
negative (red) electrical potentials of theN1-VHHm surface are shown. The VHHCDR3 regions are represented in a white ribbon structure. The symbols * and °
indicate N1-VHHm from the same clonal families. (E) ELISA of the binding of the 13 N1-VHHm candidates to N1rec protein. N1rec (N1rec-tGCN4, filled
circles) or recombinant M2e-tGCN4 (filled squares) at 10 g/ml was used for coating. Dilution series of the 13 N1-VHHm candidates (His tagged) were
incubated in the wells of coated plates, andmouse anti-His tag-HRP was used to reveal binding. OD, optical density. (F) SPR sensorgram of N1-VHHmbinding
to N1rec. The x axis shows time (seconds), and the y axis shows resonance units (RU), reflecting the increase in mass. N1rec was immobilized on a CM5 chip by
chemical linkage. At 120 s,N1-3-VHHmwas injected into the chip channel. At 180 s,N1-1-VHHm,N1-3-VHHm,N1-5-VHHm,N1-6-VHHm, orN1-7-VHHm
was injected into the N1rec/N1-3VHHm-loaded channels.
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tential was predicted with the open source software ESyPred3D and visu-
alized with DeepView (50) (Fig. 1C and D).
Enzyme-linked immunosorbent assays (ELISAs). N1rec or M2e-
tGCN4 (44) at 10g/ml was used to coat 96-wellMaxiSorp (Nunc) plates
overnight at 100l/well. Blockingwas performed overnight with 5% skim
milk in PBS. Dilution series of the 13N1-VHHmcandidates (from 10M
to 0.1 nM) were incubated for 2 h at 37°C, and excess VHH was removed
by three washes with PBS containing 0.05% Tween 20. Binding of the
N1-VHHmtoN1rec tGCN4 orNA globular headmoieties was assessed by
a mouse anti-His tag Ab fused with HRP (1:5,000). After three washes
with PBS, 100 l of TMB substrate (Pharmingen BD) was added, and
absorbance at 450 nm was measured.
N1-VHHm SPR analysis. The affinity of monovalent N1-3-VHHm,
N1-5-VHHm, and N1-7-VHHm for N1rec was determined by surface
plasmon resonance (SPR) on a Biacore 3000 platform (GE Healthcare).
N1rec antigen was first immobilized (2,000 resonance units) in Series S
Sensor Chip CM5 (GE Healthcare) by chemical NH2 coupling in 10 mM
NaAc (pH4.5). N1rec-loaded channels were regeneratedwith 0.02%SDS.
Each monovalent N1-VHHmwas diluted in HBS buffer (0.01 MHEPES,
0.15MNaCl, 0.005%Tween 20, pH6.4) to obtain a gradient ranging from
1.95 to 1,000 nM. The different N1-VHHs were injected over the N1rec-
coated chip to record their binding kinetics. Biacore T00 evaluation soft-
ware was used to calculate association rate constants (Kon), dissociation
rate constants (Koff), and equilibrium dissociation constants (KD Koff/
Kon).
Construction of bacterium-produced bivalent N1-VHH (N1-
VHHb).The coding information forN1-3-VHHmandN1-5-VHHmwas
amplified with primers MH (CATGCCATGGGAGCTTTGGGAGCTTT
GGAGCTGGGGGTCTTCGCTGTGGTGCGCTGAGGAGACGGTGAC
CTGGGT) and A4short (CATGCCATGATCCGCGGCCCAGCCGGCC
ATGGCTGATGTGCAGCTGGTGGAGTCT) to introduce an NcoI
restriction enzyme site at each end of the amplified fragment. The MH
primer also introduced the hinge sequence of llama 
2c (AHHSEDPSSK
APKAPMA) (51) to separate the two N1-VHHm domains. PCR ampli-
cons of N1-3-VHHm and N1-5-VHHm were cloned into plasmid
pHEN6c containing the n1-3-vhh or n1-5-vhh gene in order to generate
homobivalent N1-3-VHHb and N1-5-VHHb expression constructs,
which also contained a carboxy-terminal hexahistidine tag (Fig. 1B).
These bivalent constructs were expressed and purified from the periplas-
mic fraction of E. coli as outlined above. We used an irrelevant, bivalent,
in-tandem-fused VHH specific for bacterial-lactamase (BL-VHHb) as a
negative control (52) (kindly provided by Trong Nguyen-Duc, VUB,
Brussels, Belgium). The endotoxin levels of the bivalent VHH prepara-
tions were determined as described above.
Production of bivalent N1-VHHb fused to the mouse IgG2 Fc frag-
ment (N1-VHH-Fc) in seeds of stably transformed A. thaliana lines.
The three different n1-vhh-fc sequences coding for N1-3-VHHm, N1-5-
VHHm, and N1-7-VHHm fused at the amino-terminal end with the 2S2
signal peptide and at the carboxy-terminal end with the Fc region of
mouse IgG2a and the KDEL retention signal were synthesized commer-
cially (GenScript) and cloned into a PphasGW binary transfer DNA (T-
DNA) vector, resulting in the PphasGWn1-vhh-fc vector (Fig. 1B). The
coronavirus GP4 subunit protein fused to the samemouse IgG2a Fc moi-
ety (GP4-Fc; kindly provided by Robin Piron, VIB and Ghent University)
was used as an irrelevant control in the antiviral assays. Agrobacterium
C58C1Rifr(pMP90) was transformed with the PphasGWn1-3-vhh-fc,
PphasGWn1-5-vhh-fc, PphasGWn1-7-vhh-fc, or PphasGWGP4-fc con-
struct.
Agrobacterium C58C1Rifr(pMP90) was transformed with the
PphasGWn1-3-vhh-fc, PphasGWn1-5-vhh-fc, PphasGWn1-7-vhh-fc, and
PphasGWGP4-fc binary T-DNA vectors, and the resulting strains were
used for A. thaliana floral-dip transformation (53, 54). Generations T1 to
T3 were produced and screened for the best N1-VHH-Fc expressers. For
protein purification, 1 g of transformed A. thaliana seeds was crushed in
25 ml of 50 mM Tris-HCl (pH 8.0)–200 mM NaCl–5 mM EDTA–0.1%
(vol/vol) Tween 20–Complete protease inhibitor tablets (Roche). The
seed extracts were clarified by centrifugation and applied to a protein G
Sepharose column (GE Healthcare). N1-VHH-Fc proteins were eluted in
0.1 M glycine (pH 3.0) and immediately neutralized with 1 M Tris-HCl
(pH 9.0). Between 1 and 10 mg of N1-VHH-Fc was recovered. The endo-
toxin levels of the VHH-Fc preparations were determined as described
above.
Plaque assays.Monolayers of MDCK cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal calf
serum, 1% penicillin–streptomycin, and 1% glutamine and nonessential
amino acids at 37°C in 5% CO2. TMPRSS2-expressing MDCK cells
(kindly provided by Wolfgang Garten, Philipps-Universität Marburg,
Marburg, Germany) were cultured in DMEM supplemented with the in-
gredients described above, as well as Geneticin (0.3 mg/ml) and puromy-
cin (2g/ml). Expression of TMPRSS2was inducedwith doxycycline (0.5
g/ml) (55). At 70% confluence, the MDCK cells were infected at a mul-
tiplicity of infection of 10 with NIBRG-14ma, NIBRG-23, or H5N1
H274Yma. Samples containing monovalent N1-3/5/7-VHHm, bivalent
N1-3/5-VHHb, bivalent N1-3/5/7/GP4-VHH-Fc, oseltamivir, or control
medium were mixed with 0.8% Avicel RC-591 as an overlay (56). After 2
to 4 days of incubation, the cells were fixed with 4% paraformaldehyde in
PBS for 30 min. The cells were permeabilized with 20 mM glycine con-
taining 0.5% (vol/vol) Triton X-100. After blocking with bovine serum
albumin (BSA), the cells were incubated for 2 h with polyclonal anti-
NIBRG-14 (1:1,000) or anti-M2e monoclonal Ab (MAb; 1:5,000). After
washing, anti-mouse whole IgG-HRP was used to visualize plaques with
the TrueBlue peroxidase substrate (KPL).
Mouse experiments. All mouse experiments were conducted accord-
ing to national (Belgian Law 14/08/1986 and 22/12/2003 and Belgian
Royal Decree 06/04/2010) and European legislation (EU Directives 2010/
63/EU and 86/609/EEG) on animal regulations. All experiments on mice
were approved by the ethics committee ofGhentUniversity (permit num-
ber LA1400091), and efforts were made to avoid or diminish animal suf-
fering. Specific-pathogen-free female BALB/c mice 7 to 9 weeks old were
purchased from Charles River (Germany) and used in all experiments.
Mice were housed in ventilated cages with high-efficiency particulate air
filters in temperature-controlled, air-conditioned facilities and had food
and water ad libitum. Mice were anesthetized by intraperitoneal injection
of xylazine (10 g/g) and ketamine (100 g/g) before the intranasal ad-
ministration of N1-VHHm, N1-VHHb, or N1-VHH-Fc. The N1-VHHm
in any format were diluted in endotoxin-free PBS with 1% (wt/vol) BSA
and applied intranasally in doses ranging from 0.25 to 5 mg/kg, as indi-
cated in the figure legends. Mice were challenged 4 or 24 h later, as indi-
cated, with 6 LD50s (H5N1H274Yma) or 4 LD50s (NIBRG-14ma) of virus
(50 l, divided equally between the nostrils). A 30% loss of body weight
was the endpoint at which sick mice were euthanized. On day 4 after the
challenge, lung homogenates were prepared in PBS, cleared by centrifu-
gation at 4°C, and used for virus titration. Monolayers of MDCK cells
were infectedwith 50l of serial 1:10 dilutions of the lung homogenates in
the wells of a 96-well plate in serum-free Dulbecco’s modified Eagle me-
dium (Invitrogen) supplemented with L-glutamine, nonessential amino
acids, penicillin, and streptomycin. After 1 h, the inoculum was replaced
with medium containing 2 g/ml of L-1-tosylamide-2-phenylethyl chlo-
romethyl ketone (TPCK)-treated trypsin (Sigma-Aldrich). Endpoint vi-
rus titers were determined by hemagglutination of chicken red blood cells
and expressed as TCID50s per milliliter. IAV RNA levels were determined
by quantitative reverse transcription-PCR (RT-qPCR). RNA was isolated
from 150 l of cleared lung homogenate with the NucleoSpin RNA virus
kit (Macherey-Nagel). The relative amount of NIBRG-14ma genomic
RNA was determined by preparing viral cDNA and performing quantita-
tive PCR with M-genomic segment primers CGAAAGGAACAGCAGAGT
andCCAGCTCTATGCTGACAAAATGandprobeGGATGCTG(probeno.
89; Universal Probe Library, Roche) and the LightCycler 480 real-time PCR
system (Roche).
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Selection and characterization of H5N1 N1-VHHm escape mutant
viruses.NIBRG-14ma virus was serially diluted and used to infectMDCK
cells in the presence ofN1-3-VHHm(4.2M)orN1-5-VHHm(3.7M),
a dose corresponding to 10 times the 50% inhibitory concentration (IC50)
(see Table 2). Escape mutants were screened by monitoring cytopathic
effects. After nine passages in the presence of N1-3-VHHm or N1-5-
VHHm, escape viruses were plaque purified by growth on MDCK cells
overlaid with 0.6% low-melting-point agarose in the presence of N1-3-
VHHm or N1-5-VHHm. Escape virus isolates were amplified on MDCK
cells, still in the presence of 10 times the IC50 of N1-3-VHHm or N1-5-
VHHm. Total RNAwas extracted from the supernatant and used to clone
the cDNA corresponding to the NA viral RNA segment (57). Deduced
amino acid substitutions in the NA sequence of escape viruses were mod-
eled with PyMol (Delano Scientific; http://www.pymol.org) by using the
H5N1 NA structure derived from A/Vietnam/1194/2004 (Protein Data
Bank [PDB] code 2HTY). N1-VHH binding assays were performed as
described previously (35). Briefly, 4 to 8 HA units of wild-type or plaque-
purified candidate escape virus was used to coat the wells of ELISA plates.
After blocking, the plates were incubated with different concentrations of
N1-3-VHHm, N1-3-VHHb, N1-5-VHHm, or N1-5-VHHb. Binding of
N1-VHHswas revealed by incubationwith an anti-His tagMAb, followed
by a secondary sheep anti-mouse IgG Ab conjugated to HRP and visual-
ized by the addition of TMB substrate, and absorbance at 450 and 655 nm
was measured.
Statistical analysis. GraphPad software (GraphPad Prism, version 6)
was used for statistical analysis. To compare two groups in the fetuin and
AVINAs, a t test was used. Differences betweenmouse groups were tested
by two-way analysis of variance (ANOVA). When this test demonstrated
a significant difference between groups (P 	 0.05), t tests were used to
compare two groups on each day. Kaplan-Meier survival curves were
plotted, and differences in survival were analyzed by the Mantel-Cox log
rank test.
RESULTS
Production of recombinant tetrameric NA. A baculovirus ex-
pression vector system was used to produce recombinant sol-
uble tetrameric and enzymatically active H5N1 NA derived
from A/crested eagle/Belgium/01/2004 (N1rec). The N1rec
coding sequence was cloned into a pAcMP2 expression vector
(pAcMP2n1rec) under the control of the AcNPV basic protein
promoter, which is active in the late phase of the baculovirus in-
fection cycle (Fig. 1A). Infection of S. frugiperda (Sf9) cells with
recombinant baculovirus AcNPVN1rec resulted in sialidase activ-
ity in the cell supernatant, suggesting that the N1rec product was
soluble and enzymatically active NA (Fig. 1A). N1rec protein was
purified from the supernatant of infected Sf9 cells by three succes-
sive chromatography steps, including size exclusion chromatog-
raphy to collect tetrameric N1rec (see Materials and Methods).
Using 4-MUNANA as a substrate, we calculated that purified
N1rec had a specific activity of 56,851 NA U/mg.
Immunization and VHH phage library construction. N1rec
was used as an antigen for the generation and selection of NA-
specific VHH. From an immunized alpaca, we obtained a VHH
phage library of 2  108 independent transformants, 57% of
which had a cDNA insert of the correct size (data not shown).
Seventy-eight positive clones were selected, 13 of which had
unique VHH sequences. CDR3 had the most variable amino acid
sequence of the 13 N1rec-binding VHHs (N1-VHHm) (Fig. 1C).
In silico structure prediction of the monomeric N1-VHHm can-
didates showed that the CDR3 of N1-1-VHHm, N1-3-VHHm,
N1-4-VHHm,N1-5-VHHm, andN1-6-VHHmhad an electrone-
gative protruding paratope (Fig. 1D).
Production and characterization of soluble monomeric N1-
VHHm. The binding of the N1-VHHm proteins to N1rec was
assessed by ELISA and comparedwith binding to the recombinant
M2e-tGCN4 protein, which contains the same tetramerizing leu-
cine zipper as N1rec (Table 1 and Fig. 1E). Except for N1-11-
VHHm and N1-13-VHHm, none of the N1-VHHm proteins
bound substantially to the recombinant M2e-tGCN4 protein. We
next used the 4-MUNANA substrate to assess the ability of the
N1-VHHm candidates to inhibit the enzymatic activity of N1rec.
Four candidates, N1-1-VHHm,N1-3-VHHm,N1-5-VHHm, and
N1-6-VHHm, inhibited the catalytic activity of N1rec (Table 1).
N1-3-VHHmandN1-5-VHHm inhibitedN1rec in the submicro-
molar range (Table 2) and, together with N1-7-VHHm, was ana-
lyzed by SPR to determine its affinity for immobilizedN1rec. Both
N1-3-VHHm and N1-5-VHHm had a high affinity for N1rec,
with aKD in the lownanomolar (N1-5-VHHm) to high picomolar
(N1-3-VHHm) range. N1-7-VHHm showed approximately 10-
to 100-fold lower affinity for N1rec than N1-5-VHHm and N1-3-
VHHm, respectively (Table 1). These binding affinities of N1-3-
VHHm and N1-5-VHHm for N1rec resemble the affinities
reported for a monomeric VHH that inhibits the activity of ly-
sozyme (33). Competitive SPR analysis also showed that prior
binding of N1-3-VHHm toN1rec abolished the subsequent bind-
ing of N1-1-VHHm, N1-5-VHHm, and N1-6-VHHm. Con-
versely, N1-7-VHHm binding to N1rec was not affected by prior
incubation ofN1recwithN1-3-VHHmorN1-5-VHHm(Fig. 1F).
This suggests that N1-3-VHHm and N1-5-VHHm bind an over-
lapping epitope within N1rec or that binding of N1-3-VHHm
sterically hinders the binding ofN1-5-VHHmwhileN1-7-VHHm
binds a different epitope.
We next analyzed the antiviral potential of N1-3-VHHm and
N1-5-VHHm by using H5N1 strain NIBRG-14ma. The amino
acid sequences of the NA of NIBRG-14ma (derived from A/Viet-
nam/1194/2004) and N1rec (derived from A/crested eagle/Bel-
gium/01/2004) are highly homologous, with only 13 amino acid
differences, none of whichmap in or close to the NA catalytic site.
In the presence of N1-3-VHHm or N1-5-VHHm, the size of
NIBRG-14ma plaques was reduced in a concentration-dependent
manner, with IC50s in the low nanomolar range (Table 2). In con-
TABLE 1 Characteristics of N1-VHHm binding to purified







(M1 s1) Koff (s
1) KD (M)
1   NDb ND ND
2   ND ND ND
3   3.6 E6 1.3 E3 3.7 E10
4   ND ND ND
5   1.2 E5 5.8 E4 4.7 E9
6   ND ND ND
7   4.4 E4 2.8 E3 6.3 E8
8   ND ND ND
9   ND ND ND
10   ND ND ND
11   ND ND ND
12   ND ND ND
13   ND ND ND
a Binding of N1rec (recombinant tetrameric N1 NA) was determined by ELISA. A
minus sign indicates binding to the tetramerizing zipper and to N1rec.
b ND, not done.
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trast, N1-7-VHHm did not affect the size or number of NIBRG-
14ma plaques (Table 2). These results indicate that the in vitro
antiviral potential of NA-specific VHH proteins depends on their
NA-inhibitory activity.
Bivalent N1-VHHb formats have enhanced NA-inhibitory
and antiviral potential. It has been reported that the generation of
multivalent formats of VHHs increases their functional affinity by
introducing avidity (34). For example, the introduction of avidity
drastically decreased the Koff of the VHH molecules directed
against lysozyme and significantly improved their enzyme-inhib-
itory activity over that of their monovalent format (51). To in-
crease the avidity of N1-VHHm, we compared two different biva-
lent formats. In one approach, we used the llama IgG2c hinge (17
amino acid residues) as a flexible linker to fuse two identical N1-
VHHm gene moieties in tandem, resulting in the bivalent n1-3-
vhhb andn1-5-vhhb expression elements (Fig. 1B and 2A).Despite
repeated attempts, we could not generate an N1-7-VHHb expres-
sion plasmid. The corresponding proteinswere expressed inE. coli
and purified, and their in vitro N1-VHHb NA-inhibitory and an-
tiviral activities were compared with those of their monovalent
counterparts. N1rec inhibition by N1-3-VHHb and N1-5-VHHb
was 2,000- and 500-fold stronger than that by the corresponding
N1-3-VHHm and N1-5-VHHm formats, respectively (Table 2).
Surprisingly, in a plaque assay using MDCK cells infected with
NIBRG-14ma virus, both N1-3-VHHb and N1-5-VHHb seem-
ingly had antiviral activities that were comparable to the activities
of their monovalent counterparts (data not shown). In this assay,
exogenous trypsin is used to facilitate the maturation of HA in
newly produced virions to allow multicycle replication of the re-
combinant NIBRG-14ma virus. We noticed that the llama IgG2c
hinge linker used to generate bivalent VHH formats was sensitive
to trypsin cleavage (Fig. 2A). To circumvent the use of exoge-
nously added trypsin, we took advantage of TMPRSS2-expressing
MDCK cells, which are transformed with the doxycycline-induc-
ible serine protease TMPRSS2 and allow multicycle replication of
IAV in the absence of exogenous trypsin (55). By using monolay-
ers of TMPRSS2-expressing MDCK cells for infection with
NIBRG-14ma, the antiviral effect of N1-3-VHHb and N1-5-
VHHb was 240- and 58-fold greater, respectively, than that of
their monovalent formats (Table 2). These results obtained with
N1-VHHb indicate that the NA-inhibitory and antiviral activities
of both bivalent N1-VHHb formats are significantly greater than
those of the monovalent N1-VHHm formats.
We next engineered N1-VHH variants fused to a mouse
IgG2a-derived Fc domain as an alternative bivalent format (N1-
Vhh-Fc). To produce these more complex proteins, we used a
robust plant seed-based expression system with a reported high
yield of recombinant Abs (58, 59). For this, the n1-3-vhh, n1-5-
vhh, and n1-7-vhh genes were fused to the sequence encoding the
hinge and Fc tail of mouse IgG2a (n1-vhh-fc). These n1-vhh-fc
constructs were cloned into the binary vector Pphas as a T-DNA
expression cassette (Fig. 1B and 2B). Subsequently, transgenic A.
thaliana plants were generated byAgrobacterium-mediated floral-
dip transformation. Seed extracts of segregating T3 Arabidopsis
transformants were screened by ELISA with Abs against the Fc
part for the best expressers of the recombinant dimeric N1-
VHH-Fc proteins. N1-3-VHH-Fc and N1-5-VHH-Fc accumu-
lated to high levels in several transformants, and total soluble seed
protein levels of 16%were found.On the contrary, N1-7-VHH-Fc
did not accumulate well and the best expressors contained
VHH-Fc at about 1% of their total soluble seed protein (data not
shown). A good correlation was observed between the ELISA re-
sult and NA-inhibitory activity in crude seed extracts from differ-
ent T3 transformants (data not shown). N1-3-VHH-Fc, N1-5-
VHH-Fc, and N1-7-VHH-Fc were purified from seed extracts by
protein G affinity chromatography. Reducing SDS-PAGE and
Coomassie staining showed that the N1-VHH-Fc monomers mi-
grated at approximately 42 kDa (Fig. 2B). N1-3-VHH-Fc andN1-
5-VHH-Fc had stronger N1rec inhibition capacity and in vitro
antiviral activity than their monovalent N1-3-VHHm and N1-5-
VHHm counterparts (Table 2). Bivalent N1-7-VHH-Fc bound to
N1rec in ELISAs (data not shown), but it failed to inhibit N1rec
and the H5N1 viruses in vitro. Taken together, these results indi-
cate that in vitro NA inhibition and antiviral activity against
NIBRG-14ma are enhanced at least 30-fold by using bivalent N1-









H274Yb Foldc NIBRG-23b Foldc
N1-3-VHHm 425.2 149.4 1,844 344.3 6,440 1,247 4,295 2,835.4
N1-5-VHHm 374.9 118.5 848.5 380.2 26,500 3,492 2,967.6
N1-7-VHHm 15,448 32,896 32,896 32,896
SA-VHHmd 15,448 32,896 32,896 32,896
N1-3-VHHb 0.157 0.206 2,708 7.6 3.0 240 52.2 36.8 123 24.6 31.9 174
N1-5-VHHb 0.69 0.231 543 14.5 11.1 58 707.5 23.6 3.8 148
BL-VHHbe 15,448 32,896 32,896 32,896
N1-3-VHH-Fc 1.31 0.605 324 23.08 79 89.4 7.8 71 24.2 3.7 177
N1-5-VHH-Fc 1.49 0.746 251 28.14 30 17,083 27.03 129
N1-7-VHH-Fc 7,900 5,260 5,260 5,260
GP4-Fcf 7,900 5,260 5,260 5,260
Oseltamivir 586.1 120.5 15,030 10,039 243,000 73,000
a Mean IC50 from three independent NA inhibition assays with 4-MUNANA and 160 ng of N1rec.
b Mean plaque IC50 from two independent plaque assays performed in duplicate in which the VHH concentration reduced the plaque size by 50% compared with mock VHH.
c Fold increase in the inhibitory potency of the N1-VHH bivalent format compared with its monovalent format.
d Monomeric VHH against seed storage albumin.
e Bivalent VHH against bacterial -lactamase.
f Coronavirus GP4 protein fused to mouse IgG2a Fc.
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VHHb and N1-VHH-Fc formats, compared with those of the
monovalent N1-VHHm domain.
In vitro antiviral activity ofN1-VHHagainst clade 2.2H5N1,
oseltamivir-resistant H5N1, and 2009 pandemic H1N1 viruses.
Like NA from NIBRG-14, N1rec NA (derived from A/crested ea-
gle/Belgium/01/2004) belongs to clade 1 of the H5N1 NAs. To
assess the potential cross-reactivity of the NA activity inhibition
(NAI) of the isolated VHHs in the three available formats
(N1-VHHm, N1-VHHb, and N1-VHH-Fc), we focused first on
NIBRG-23 NA (derived from A/turkey/Turkey/01/2005), a clade
2.2 H5N1 virus (60). Although there are only a few laboratory-
confirmed human infections with H5N1, it appears that clade 2
H5N1 viruses are responsible formost of these zoonotic infections
with HPAIV (61). N1-3-VHHm andN1-5-VHHm reduced the in
vitro growth of the NIBRG-23 virus with an IC50 in the lowmicro-
molar range (Table 2). N1-3-VHHb, N1-5-VHHb, N1-3-VHH-
Fc, and N1-5-VHH-Fc displayed about 150-fold higher in vitro
antiviral activity than the corresponding monovalent N1-VHHm
form against this clade 2 virus in a plaque size reduction assay. On
the basis of these findings, we conclude that the two NA-inhib-
itory VHHs inhibit the in vitro replication of representative
H5N1 IAV from clades 1 and 2 with comparable efficiency,
suggesting that they target an epitope that the NAs of these
viruses have in common.
Oseltamivir-resistant IAV frequently emerges and spreads in
the human population. Several mutations have been reported to
contribute to oseltamivir resistance, but among them, the H274Y
mutation (N2 numbering) is the one most commonly found in
oseltamivir-resistant viruses (62). We used reverse genetics to
generate a clade 1 H5N1 virus harboring the H274Y mutation in
NA (derived from A/crested eagle/Belgium/01/2004), while the
HA segment was derived from NIBRG-14 and the remaining six
segments were from PR/8, resulting in an H274Y mutant H5N1
virus. Next, we determined if N1-3-VHHm, N1-5-VHHm, N1-3-
VHHb, N1-5-VHHHb, N1-3-VHH-Fc, andN1-5-VHH-Fc could
inhibit this virus. As all of the N1-3-VHH formats tested so far
performed like N1-5-VHH formats in vitro, we were surprised
that only N1-3-VHH (monovalent and both bivalent formats),
but not N1-5-VHH in any format, reduced the growth of H5N1
H274Y (Table 2). Compared to NIBRG-14ma, the H5N1 H274Y
IC50s were 3- to 7-fold higher but still in the low nanomolar range.
Even though the competitive SPR analysis suggested that the N1-
3-VHHm and N1-5-VHHm epitopes in NA overlap (Fig. 1F), the
contact residues necessary for their binding are probably not iden-
tical. We conclude that the three formats of N1-3-VHH evaluated
can inhibit the growth of the H5N1 H274Y virus in vitro and that
both bivalent formats have enhanced in vitro antiviral activity. In
addition, theH274Ymutation seems to be sufficient to abolish the
in vitro antiviral effect of the N1-5-VHH formats.
Next, we tested the antiviral potential of all of the N1-3-VHH
and N1-5-VHH formats against a pandemic H1N1 2009 virus
isolate (pH1N1). We used fetuin and 4-MUNANA (AVINA) as
two alternative substrates for virion-associated NA activity. With
NIBRG-14ma, and on the basis of 4-MUNANA hydrolysis, mon-
FIG 2 N1-VHHmonovalent and bivalent formats. (A) The llama IgG2c-derived hinge is sensitive to trypsin. Shown is Coomassie-stained reducing SDS-PAGE
of purifiedN1-3-VHHm,N1-5-VHHm,N1-3-VHHb, andN1-5-VHHb incubated for 60min at 37°C in the presence or absence of trypsin at 1 or 10g/ml. The
N1-VHHbmolecules migrate at about 32 kDa, and N1-VHHm and the cleavage products of N1-VHHbmigrate as bands of about 17 kDa. The diagrams on the
right depict N1-VHHm and N1-VHHb (consisting of two N1-VHHm moieties in tandem, linked by a llama IgG2c hinge of 17 amino acid residues). (B)
Coomassie-stained reducing SDS-PAGE of the fractions eluted from a protein G column purification step with seed extracts of transgenic A. thaliana T3 plants
expressing the N1-VHH-Fc proteins indicated. The N1-VHH-Fc constructs migrate at about 42 kDa. A degradation product (*) of about 28 kDa, corresponding
to the Fc moiety only, is visible. The diagram on the right shows an N1-VHH-Fc molecule consisting of two N1-VHHm moieties fused to mouse IgG2a Fc,
dimerized through a disulfide bond (green stars). The values beside the lanes are molecular sizes in kilodaltons.
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ovalent N1-3-VHHm and N1-5-VHHm had significant inhibi-
tory activity, compared with the negative controls SA-VHHm
(P 	 0.05) and PBS (P 	 0.01), although this tendency was not
significant in the fetuin assay (Fig. 3A). We attribute these differ-
ences between the two assays to the types of substrate used, the
smallmolecule 4-MUNANAversus fetuin, which is a large protein
carryingmultiple sialylated glycans. In the case of fetuin, HA plays
an important role in recruiting NA to the substrate, which may
alter the accessibility of theNA target for theN1-VHHs.We found
that the bivalent molecules N1-3-VHHb, N1-5-VHHb, N1-3-
VHH-Fc, and N1-5-VHH-Fc significantly inhibited NA activity
on both substrates (P	 0.01, Fig. 3A).
In line with our previous results with H5N1 H274Y IAV, only
N1-3-VHHb and N1-3-VHH-Fc showed NAI activity on both
substrates (P 	 0.05 or P 	 0.01) (Fig. 3B). N1-5-VHHb and
N1-5-VHH-Fc showed inhibitory potential against pH1N1 in
both assays (P	 0.05) (Fig. 3C). We could not detect binding of
the N1-VHHs to A/NewCaledonia/20/99 or inhibition of NA ac-
tivity of this virus (Fig. 3D anddata not shown). TheseAVINAand
fetuin results for NIBRG-14ma and H5N1 H274Y NA are in ac-
cordance with the N1rec inhibition and the plaque size reduction
assays mentioned before (Table 2). In addition, both bivalent N1-
5-VHHb formats inhibited pH1N1 virion-associated NA activity,
suggesting a degree of intrasubtype inhibitory effect of the N1-
VHHs.
N1-3-VHHm and N1-5-VHHm treatments reduce early
morbidity but not viral lung titers in H5N1-challenged mice.
We next evaluated the in vivo antiviral effect of N1-3-VHHm and
N1-5-VHHm. The endotoxin levels of the VHHpreparations that
were used in vivo were low and comparable for the NA-specific
VHHproteins and their irrelevant control counterparts (Table 3).
In the first experiment we administered 100 g of N1-3-VHHm,
N1-5-VHHm, or N1-7-VHHm intranasally to BALB/c mice 4 h
before a challengewith 4 LD50s ofNIBRG-14ma. Two groupswere
included as positive controls, (i) a group of mice that received 30
g of H5-VHHb, a bivalent NIBRG-14ma HA-neutralizing VHH
(36), and (ii) a group ofmice that received a large daily oral dose of
oseltamivir (45 mg/kg/day). Mice treated with N1-3-VHHm or
N1-5-VHHm showed significantly reduced morbidity at 72 and
96 h after infection compared with the groups treated with N1-7-
VHHm and PBS (P	 0.001) (Fig. 4A). Four days after infection,
themice were sacrificed to determine lung virus titers by endpoint
dilution in a TCID50 assay. All of the groups of treated mice (N1-
3-VHHm,N1-5-VHHm,N1-7-VHHm, SA-VHHm, PBS, and os-
eltamivir), except theH5-VHHb group, had large lung virus loads
ranging from 104.75 to 106.48 TCID50s/ml (data not shown). We
alsomeasured the amounts of viral RNA in the lung homogenates
by a genome strand-specific RT-qPCR method. Except for the
samples derived from theH5-VHHb-treatedmice (P	 0.001), all
of the N1-VHH-treated groups showed high viral RNA levels 96 h
after infection, comparable to those of the PBS-treated group (Fig.
4B). NA activity in the lung homogenates of the treated groups,
measured by AVINA, indicated that there was no difference be-
tween theN1-VHH- and PBS-treated groups, whereasNA activity
was strongly reduced in the H5-VHHb and oseltamivir groups
(Fig. 4C). These results are in line with the RT-qPCR results and
confirmed the presence of a high viral titer in the lung homoge-
nates of theN1-VHHgroups, despite lowmorbidity.We speculate
that the N1-VHH treatment did not have a major impact on virus
entry in this in vivo challenge model but rather reduced virus
spread within the lung compartment. A recent systems analysis of
IAV-associated pathology in the mouse revealed a positive corre-
lation between virus spread in the lung tissue and high pathoge-
nicity irrespective of the number of infectious virus particles that
were produced (63). In addition, shearing forces that are gener-
ated during the preparation of lung homogenates may have re-
leased virions from the cell membranes, which release was hin-
dered in the intact lung by NA-inhibitory Nanobodies. We
conclude that intranasal administration of N1-3-VHHm and N1-
5-VHHm prevents body weight loss after a challenge with
NIBRG-14ma virus during the early stage of H5N1 IAV infection,
without an apparent decrease in viral titer in the lung homoge-
nates.
Protection by bivalent N1-VHHb against an H5N1 chal-
lenge.The in vitro results indicated that the potency of the bivalent
formats of the inhibitory N1-VHHs against the tested H5N1 vi-
ruses was 30- to 240-fold higher than that of their monovalent
counterparts (Table 2). We therefore assessed if this heightened
antiviral effect would also be reflected in an in vivo challenge ex-
periment. We first determined the protective potential during the
early stages of H5N1 infection. Four hours before a challenge with
4 LD50s of NIBRG-14ma, groups of BALB/c mice were intrana-
sally given 60 g of N1-3-VHHb, N1-5-VHHb, or BL-VHHb (a
bivalent VHH directed against the irrelevant bacterial target
-lactamase) and 84 g of N1-3-VHH-Fc, N1-5-VHH-Fc, or
GP4-Fc (a plant-produced coronavirus GP4-Fc fusion protein).
Treatment with N1-3-VHHb or N1-3-VHH-Fc significantly im-
proved morbidity at 72 and 96 h postinfection (hpi) compared
with that of the GP4-Fc and PBS negative-control groups (P 	
0.001) (Fig. 4D). The protection against weight loss was compa-
rable to that observed in the positive controls (H5-VHHb and
oseltamivir [the latter was given daily at 45mg/kg/day by gavage]).
Treatment with the bivalent formats of N1-5-VHH resulted in a
reduction of morbidity that was significant at 60, 72, and 96 hpi
comparedwith that of the negative controls (P	 0.001) (Fig. 4D).
Determination of the lung virus load on day 4 after a challenge
revealed that all of the challenged groups, except H5-VHHb-
treatedmice (no virus detectable), had large and comparable lung
virus loads (data not shown). In addition, the NA activity in the
lung homogenates of the groups treated with N1-VHH bivalent
formatswas assessed by anAVINA. The lung homogenates treated
with bivalent N1-VHHs (N1-3-VHHb, N1-5-VHHb, N1-3-
VHH-Fc, and N1-5-VHH-Fc) showed 2- to 5-fold decreases in
NA activity compared to that of the BL-VHHb (P 	 0.001)-,
GP4-Fc (P 	 0.05 or P 	 0.01)-, and PBS (P 	 0.01)-treated
groups (Fig. 4E). This could be attributable to residual inhibitory
bivalentN1-VHHb in the lung preparation, possibly because of an
increased half-life of the bivalent N1-VHHs, relative to that of
N1-VHHm, for which no significant reduction in lung-associated
NA activity was demonstrated (Fig. 4C). Taken together, these
results show that treatments with bivalent formats of N1-3-VHH
andN1-5-VHH improve protection during the first 4 days follow-
ing an NIBRG-14ma challenge and reduce lung-associated NA
activity, a surrogate for the viral load, in H5N1-infected mouse
lungs.
Dose-dependent protection against an H5N1 challenge. To
test if prophylactic administration of N1-3-VHHb, N1-3-VHH-
Fc, N1-5-VHHb, or N1-5-VHH-Fc can protect mice against a
lethal challenge with NIBRG-14ma (4 LD50s), we repeated the
protection studies and monitored the mice for 2 weeks. We fo-
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FIG 3 N1-VHH inhibits NA activity from NIBRG-14ma, H5N1 H274Y, and pH1N1 virions. Fetuin (left) and 4-MUNANA (right) were used as substrates. (A)
NIBRG-14ma NA inhibition. (B) H5N1 H274Y oseltamivir-resistant NAI. (C) Pandemic H1N1 2009 NAI. SA-VHHm, monovalent VHH directed against seed
storage albumin; BL-VHHb, bivalent VHHdirected against bacterial -lactamase; GP4-Fc, coronavirus GP4 protein fused tomouse IgG2a Fc. To determine the
significance of differences between groups, a t test was used (*, P 	 0.05; **, P 	 0.01). Results are representative of two independent experiments. The bars
represent the mean optical density (OD) at 425 nm (n  3) in the fetuin assay and the mean fluorescence intensity (n  2) after 1 h of incubation in the
4-MUNANAassay. Error bars represent the standard deviation of themean. The values above the bars are normalized to the respectivemonovalent (SA-VHHm),
bivalent (BL-VHHb), and Fc chimera (GP4-Fc) controls and PBS. The significance of differences between groups and their respective controls was determined
by a t test (*, P	 0.05; **, P	 0.01; ***, P	 0.005). (D)Mono- and bivalent NA-specific VHHs bind to H5N1 virus but not to seasonal A/NewCaledonia/20/99
virus. ELISA plates were coated with 8 HA units of NIBRG-14 or A/New Caledonia/20/99 (New Caledonia) virus. After blocking, wells were incubated with
different concentrations of N1-3-VHHm, N1-3-VHHb, N1-5-VHHm, or N1-5-VHHb as indicated (nanomolar concentration of VHH). Binding of N1-VHHs
was revealed by incubation with an anti-His tag MAb, followed by a secondary sheep anti-mouse IgG Ab conjugated to HRP and visualized by the addition of
TMB. The y axis shows the absorbance at 450 nm subtracted from the absorbance at 655 nm.
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cused on the most potent N1-VHHb bivalent formats and as-
sessed their protective efficacy in a dose-response experiment.
Groups of four BALB/cmice were treated intranasally with 60, 12,
2.5, or 0.5g of N1-3-VHHb or N1-5-VHHb. In parallel, another
group was treated daily by oral administration of oseltamivir (45
mg/kg/day). Negative-control groups were treated with 60 g of
BL-VHHb or with PBS before a challenge. Mice that had received
60 g of N1-3-VHHb, N1-5-VHHb, or BL-VHHb before the
challenge also received a second intranasal dose of 60 g of the
same bivalent VHH on day 6 after the challenge. All of the mice in
the PBS and BL-VHHb treatment groups died 9 to 10 days after
infection (Fig. 5C and D). In contrast, treatment with oseltamivir
and a large intranasal dose of N1-3-VHHb or N1-5-VHHb (60
g) protected the mice against death. In agreement with this, os-
eltamivir and N1-5-VHHb (60 g) reduced postchallenge body
weight loss compared to that of control-treated mice (Fig. 5A and
B). Although administration of the largest amount of N1-3-
VHHb prevented death, it did not affect body weight loss. A single
intranasal dose of 12 or 2.5 g of N1-3-VHHb or N1-5-VHHb
provided partial protection against death but failed to reduce
morbidity (Fig. 5A to D).
We next evaluated protection against a potentially lethal chal-
lenge with NIBRG-14ma by prior single-dose intranasal adminis-
tration of the plant-produced N1-3-VHH-Fc and N1-5-VHH-Fc
formats. N1-3-VHH-Fc (80 and 17 g), as well as oseltamivir,
prevented death following a challenge with NIBRG-14ma (Fig.
6C), whereas treatment with 3.5 g of N1-3-VHH-Fc prevented
















a The endotoxin (lipopolysaccharide [LPS]) levels (endotoxin units [EU]) in purified,
E. coli-derived (VHHm/b) and A. thaliana-derived (VHH-Fc and GP4-Fc) proteins
were determined by a Limulus amebocyte lysate-based chromogenic test and calculated
relative to an endotoxin standard.
FIG 4 Prophylactic effect of treatment with inhibitory N1-VHHm, N1-VHHb, and N1-VHH-Fc on H5N1-challenged mice. (A) Groups of 6- to 8-week-old
BALB/c mice (n  5 per group, except oseltamivir and SA-VHHm [n  4] and H5-VHHb and PBS [n  3]) were given 100 g of the N1-VHHm indicated
intranasally 4 h before a challenge with 4 LD50s of NIBRG-14ma. Intranasal administration of 30 g of H5-VHHb and daily oral administration of oseltamivir
(45 mg/kg/day, starting 4 h before a challenge) were included as positive controls. Body weight was monitored daily after a challenge and is expressed as a
percentage of the initial body weight. (B) Mice were sacrificed on day 4 after a challenge, and lung homogenates were prepared. Viral genomic RNA-specific
RT-qPCR was used as a readout of the lung viral load. The CT values of the individual mice are plotted; a horizontal line indicates the mean. (C) AVINA of lung
homogenates sampled on day 4 after infection. (D) Bivalent formats of N1-3-VHH andN1-5-VHH administered 4 h before a challenge with 4 LD50s of NIBRG-14ma
reduced morbidity. Four hours before a challenge with 4 LD50s of NIBRG-14ma, groups of BALB/c mice (n 6 per group, except BL-VHHb and PBS [n 4] and
oseltamivir and PBS [n  3]) were treated intranasally with 60 g of VHHb (N1-3-VHHb, N1-5-VHHb, or BL-VHHb) or 84 g of VHH-Fc (N1-3-VHH-Fc,
N1-5-VHH-Fc, orGP4-Fc).Mice treatedwithneutralizingH5-VHHb(30g) or oseltamivir (45mg/kg/day, daily by gavage)were included as positive controls. (E)NA
activity in lung homogenates of mice treated with bivalent N1-VHH and challenged with H5N1, as determined by AVINA. In panels A and D, each datum point
represents the average bodyweight of all of themice alive, and error bars represent standarddeviations.Differences betweenmouse groupswere determinedby two-way
ANOVA. Kaplan-Meier curves were used for survival analysis (*, P	 0.05; **, P	 0.01; ***, P	 0.001). RFU, relative fluorescence units.
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the deaths of some animals.However, the challengewas associated
with significant body weight loss for all of the doses and treat-
ments (Fig. 6A and B).
When the protective efficacies of the two bivalent formats of
N1-3-VHH and N1-5-VHH were compared, it appeared that the
Fcmoiety in theN1-VHH-Fc formats provides an extra protective
effect against morbidity (compare 60 g N1-3-VHHb with 84 g
N1-3-VHH-Fc in Fig. 5A and 6B) andmortality, following a chal-
lenge with NIBRG-14ma (Fig. 5 and 6). We conclude that a single
dose of both bivalent N1-3/5-VHH formats can protect mice
against a potentially lethal challenge with an H5N1 virus and that
Fc-fused VHHs provide better protection, suggesting that Fc re-
ceptor-binding molecules contribute to protection.
N1-3-VHHb and N1-3-VHH-Fc protect against a challenge
with oseltamivir-resistant H5N1. Our in vitro analysis demon-
strated that monovalent and bivalent formats of N1-3-VHH, but
not N1-5-VHH, reduced the growth of oseltamivir-resistant
H5N1 H274Y virus (Table 2). To evaluate these findings in vivo,
groups of six BALB/c mice received 30 g of N1-3-VHHb, N1-5-
VHHb, or BL-VHHb by intranasal administration 24 h before a
challenge with 4 LD50s of NIBRG-14ma or 6 LD50s of H5N1
H274Yma. In parallel, a group was treated by daily oral adminis-
tration of oseltamivir (1mg/kg/day), a dose that has been reported
to fully protect laboratory mice against a challenge with highly
pathogenic H5N1 (64). In line with our previous results, mice
treated with N1-3-VHHb, N1-5-VHHb, or oseltamivir suffered
from substantial but transient weight loss, but they survived a
challenge with the NIBRG-14ma virus, whereas mice receiving
PBS or BL-VHHb died before day 10 after the challenge (Fig. 7).
This result demonstrates that a single intranasal administration of
N1-3-VHHb or N1-5-VHHb is sufficient to protect against a sub-
sequent lethal challenge (24 h later) with an H5N1 virus. Follow-
ing a challengewith theH5N1H274Ymutant virus, N1-3-VHHb-
treated mice were severely sick but all of them survived (Fig. 7A
and C). All of the other groups, including the oseltamivir-treated
mice, died after a challenge with the H5N1H274Y virus by day 10
after infection (Fig. 7A and C). Taken together, these results show
that treatment of mice with bivalent N1-3-VHHb before a chal-
lenge with an oseltamivir-resistant H5N1 virus does not control
morbidity adequately but results in full recovery and survival. Fur-
thermore, bivalentN1-5-VHHbdoes not protectmice against this
challenge, suggesting that the N1-VHHb formats (i.e., tandem
repeats ofVHHseparated by a short linker) requireNA-inhibitory
activity for in vivo protection.
Finally, we compared the protective potentials of intranasally
instilled N1-3-VHH-Fc, N1-5-VHH-Fc, and N1-7-VHH-Fc in
our lethal-challenge model. Following a challenge with 4 LD50s of
NIBRG-14ma, all of the mice in the N1-3-VHH-Fc and oseltami-
vir groups lost bodyweight until day 7 after the challenge (Fig. 7B)
and then started to recover, and all of them survived the challenge
(Fig. 7D). In contrast, all of the PBS- or GP4-Fc-treated mice,
except one, became morbid and died by 10 days postinfection
(Fig. 7B and D). In the N1-7-VHH-Fc group, only one out of six
mice died after the challenge. This is very surprising because N1-
7-VHHm and N1-7-VHH-Fc have no detectable antiviral activity
in vitro. Remarkably, in this experiment, mice that had received
N1-5-VHH-Fc did not lose weight after a challenge with NIBRG-
14ma (Fig. 7B). A challenge with 6 LD50s of H5N1H274Ymutant
virus was lethal to all of the mice except those that had been pre-
treated with N1-3-VHH-Fc (all of the mice survived) or N1-7-
FIG 5 The bacterium-produced N1-VHHb formats protect H5N1-challenged mice against morbidity and death in a dose-dependent way. Groups of BALB/c
mice (n 4 per group, except the BL-VHHb, oseltamivir, and PBS groups [n 3 per group]) were given the indicated amount of N1-VHHb intranasally 24 h
before a challenge with 4 LD50s of NIBRG-14ma virus. Oseltamivir (45 mg/day/kg) was given by daily gavage starting 24 h before the challenge until day 14 after
the challenge. A single additional intranasal dose of N1-3-VHHb, N1-5VHHb, or BL-VHHb was given on day 6 after infection for the highest dose (60 g) of
these VHHs only. (A)Mice treated withN1-3-VHHb. (B) Treatment withN1-5-VHHb. (C) Survival of the N1-3-VHHb group. (D) Survival of the N1-5-VHHb
group. All mice were treated in parallel, and data for the PBS and oseltamivir groups in panels B and D are identical. In panels A and B, each point represents the
average body weight of all of the mice alive and error bars represent standard deviations. Differences in body weight between mice were determined by two-way
ANOVA. Kaplan-Meier curves were used for survival analysis (***, P	 0.001).
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VHH-Fc (four out of six mice survived), though all of the animals
lost substantial body weight (Fig. 7B and D). We conclude that
protection against a potentially lethal challenge with oseltamivir-
resistant H5N1 virus can be obtained with a single dose of N1-3-
VHH-Fc or with N1-7-VHH-Fc, although the latter construct is
less potent. This indicates that the IgG2a Fc moiety contributes to
protection, even in the absence of NA-inhibitory activity.
N1-5-VHHm escape mutants. To identify the amino acid res-
idues involved in the binding of N1-3-VHHm and N1-5-VHHm
to H5N1 NA, escape viruses were selected and plaque purified
after serial passage of NIBRG-14ma virus in MDCK cells in the
presence of a dose corresponding to 10 times the IC50 of N1-3-
VHHm or N1-5-VHHm, essentially as described before (35). Af-
ter nine passages, candidate escape mutants were plaque purified
and the NA sequences of four (N1-5-VHHm selection) and three
(N1-3-VHHm selection) isolated escape viruses were determined.
One of the escape viruses that were selected with N1-5-VHHm
contained a mutation in the NA coding region that resulted in a
change from isoleucine to threonine at position 437 in the de-
duced amino acid sequence. This substitution is located on theNA
surface, relatively close to the active site (Fig. 8A). A conservedNA
epitope that is recognized byHCA-2 under denaturing conditions
(65, 66) and localized within the NA catalytic site, and the amino
acids necessary for binding a recently reported set of MAbs that
recognize H1N1 and H5N1 NA (67) do not overlap this N1-5-
VHHm escape mutation (Fig. 8A). Sequence alignment of a set of
representative N1 IAVs, including human H1N1, other H5N1 vi-
ruses, and an avian H6N1 virus, showed that I437 is conserved in
these NA sequences (Fig. 8B). Binding studies with immobilized
virus revealed that the I437T escape virus was no longer bound by
N1-3-VHHm, N1-3-VHHb, N1-5-VHHm, and N1-5-VHHb
(Fig. 8C). This result is in accordance with the Biacore data, which
showed thatN1-3-VHHmandN1-5-VHHmcompete for binding
to recombinant H5N1 NA (Fig. 1F) and suggests that I437 is part
of the VHH epitope in NA or stabilizes the conformation of that
epitope.
Interestingly, the other three plaque-purifiedN1-5-VHHmes-
cape viruses and all three plaque-purified viruses that grew in the
presence of N1-3-VHHmcontainedwild-typeNA. Possibly, these
viruses carry compensatorymutations in other viral proteins such
as HA, as was described before for IAV passaged in vitro in the
presence of small-molecule inhibitors of NA (68). Taken together,
the results show that H5N1 viruses that overcome inhibition by
N1-3-VHHm and N1-5-VHHm can be selected in vitro and one
way of escape is through the acquisition of a mutation in NA that
results in loss of binding to the VHHs.
DISCUSSION
NA Abs usually do not neutralize virus and are thought to exert
their antiviral effects further downstream in the IAV infection
process. Still, NA-specific Abs can significantly reduce viral repli-
cation and disease severity (69, 70). Titers of Ab against N1 or N2
have been associated with high NA enzymatic activity in vaccine
preparations, suggesting that the NA content and activity of IAV
vaccines predict immunogenicity (71). NA of human influenza
viruses is subject to antigenic drift at a pace that is comparable to
that of HA (72). This suggests that NA is subject to intense im-
mune selection pressure, which is surprising given that Abs di-
rected against NA do not neutralize the virus in vitro and that
during natural infections immune responses against HA are more
pronounced than those against NA, presumably because HAmol-
ecules outnumber NA molecules on influenza virions. Biologi-
FIG 6 Plant-produced N1-VHH-Fc protects against morbidity and death after an H5N1 challenge. Groups of BALB/c mice were treated intranasally with the
amounts of N1-VHH-Fc indicated 24 h before a challenge with 4 LD50s of NIBRG-14ma. Oseltamivir (45mg/day/kg) was given to a group of threemice by daily
gavage starting 24 h before the challenge until day 14 after the challenge. An additional intranasal dose of 84g of N1-3-VHH-Fc, N1-5-VHH-Fc, or GP4-Fc was
given on day 6 after infection. (A) Relative body weights after treatment with N1-3-VHH-Fc. (B) Relative body weights after treatment with N1-5-VHH-Fc. (C,
D) The survival of N1-3-VHH-Fc-treated groups is dose dependent. The experiments shown in panels B and D were performed in parallel with those in Fig. 4,
and the PBS and oseltamivir datum points depicted are identical to those shown in Fig. 4. In panels A and B, each point represents the average body weight of all
of the mice alive and error bars represent standard deviations. Differences between mouse groups were calculated by two-way ANOVA. Kaplan-Meier curves
were used for survival analysis (**, P	 0.01; ***, P	 0.001).
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cally, HA and NA cooperate and antigenic variation in NA is, in
part, driven by antigenic escape selection pressure on HA (73).
Nevertheless, Abs directed against NA remain underexplored as a
potential influenza treatment.
Our N1-VHHs are not the first inhibitoryMAbs against H5N1
NAdescribed. Recently, IgG2bMAb 2B9 directed against clade 1
A/Vietnam/1203/04 NA showed interclade and oseltamivir-resis-
tant mutant NAI activity in vitro (74). In NAI assays with the
4-MUNANA and NA-Star substrates, the 2B9 MAb IC50s against
H5N1 clade 1 and clade 2.1 virions and against an oseltamivir-
resistant H274Y and N294S double mutant ranged from 1 to 8
g/ml. In another recent report on IgG2b MAbs targeting multi-
pleN1NAs, intrasubtypeMAbs showed relatively highH1N1NAI
potency (IC50s of 23.6 to 68.1 ng/ml), which was even lower when
A/Vietnam/1203/04 H5N1 NAI potency was assessed (IC50s of
1.41 to 2.42 g/ml) (67). We used two inhibitory N1-VHH for-
mats to assess NA-inhibitory and antiviral potentials. Results of
our N1rec inhibition assays showed that the N1-3-VHHm and
N1-5-VHHm IC50s were 425 nM (6.3 g/ml) and 374 nM (5.6
g/ml), respectively, and the introduction of bivalency (N1-
VHHb and N1-VHH-Fc) resulted in 2- to 3-log-fold further in-
creases in their inhibitory potential (5.2 to 125 ng/ml) (Table 2).
The above-mentioned conventional MAbs, which are bivalent,
have H5N1 NAI activity that is similar to that of our N1-VHHm.
We hypothesize that the much smaller size of VHH molecules
than that of conventional Abs compensates for the lack of avidity
present in conventional Abs to explain this.
Harmsen et al. reported the first VHH targeting NA (39). In
contrast to our work, where we used recombinant NA protein to
immunize an alpaca, those authors obtainedVHHby immunizing
llamas with whole IAV. This strategy yielded mainly HA and NP
binders and required a strategy of cross-selection with homolo-
gous NA, followed by further selection with recombinant NA, to
obtain NA binders. This approach resulted in VHH binding to
homologous and nonhomologous IAV, but only some of the NA
cross-binding VHHs showed NA inhibition activity (fetuin sub-
strate). It is also important to point out that the recombinant NA
activities used byHarmsen et al. were 316 to 13.5 times lower than
our N1rec specific activity (57 mol/mg/min), while their VHH
NA inhibition IC50s ranged from 124 to 2 ng/ml, with homolo-
gousNA. The apparently lower IC50s of theHarmsenVHHs (3- to
200-fold lower than that of our N1-VHHm) could therefore be
explained by a 1- to 2-log lower NA-specific subtype activity. All
together, these results suggest that a similar NAI potency range
was obtained with ourmonovalent N1-VHHm. In vitro, monova-
lent N1-3-VHHm and N1-5-VHHm had an IC50 that was almost
identical to that of oseltamivir for N1rec and for the two oselta-
mivir-sensitive H5N1 viruses we assayed (Table 2).
In the TMPRSS2-expressing MDCK-based assay, which al-
lowed us to assess multiple rounds of viral replication in the ab-
sence of exogenous trypsin, the antiviral effect of bivalent VHH
formats (N1-VHHb and N1-VHH-Fc) was clearly greater than
that of monovalent N1-VHHmmolecules (Table 2). For NIBRG-
14ma, the N1-VHH concentrations necessary to reduce the
plaque size by 50% (plaque assay IC50) for N1-3-VHHb and N1-
5-VHHb were 7.6 nM (243 ng/ml) and 14.5 nM (464 ng/ml),
respectively, which are 240- and 58-fold lower than those of their
monovalent formats. In fact, we noticed a consistent 30-fold or
FIG 7 N1-3-VHHb and N1-3-VHH-Fc, but not N1-5-VHHb and N1-5-VHH-Fc, protect against a challenge with oseltamivir-resistant H5N1 H274Y virus.
Twenty-four hours before a challenge with 4 LD50s of NIBRG-14 (N-14)ma or 6 LD50s of H274YH5N1 virus (H274Y), groups of six BALB/c mice were given 60
g of N1-3-VHHb, 60 g of N1-5-VHHb, 60 g of BL-VHHb, 84 g of N1-3-VHH-Fc, 84 g of N1-5-VHH-Fc, 84 g of N1-7-VHH-Fc, or 84 g of GP4-Fc.
An additional group of six mice was treated with oseltamivir (1 mg/day/kg) starting 24 h before the challenge. (A) Relative body weights. (C) Survival over time
after infection. NIBRG-14ma-infectedmice treated withN1-3-VHHb,N1-5-VHHb, or oseltamivir survived the challenge. Treatment withN1-3-VHHb rescued
all of the H5N1 H274Y mutant-infected mice (***, P	 0.001). (B) Relative body weights. (D) Survival over time after infection. In panels A and B, each datum
point represents the average body weight of all of the mice alive and error bars represent standard deviations. Differences between groups were evaluated by
two-way ANOVA for the body weight graphs. Kaplan-Meier curves were used for survival analysis (*, P	 0.05; **, P	 0.01; ***, P	 0.001).
NA Single-Domain Antibodies Protect against H5N1
August 2014 Volume 88 Number 15 jvi.asm.org 8291
higher inhibitory activity of bivalent N1-3-VHHb and N1-3-
VHH-Fc than of monovalent VHHs in a biochemical assay with
N1rec and against the three H5N1 viruses tested in vitro. The
H5N1 H274Y mutant was an exception in that the N1-5-VHH
mono- and bivalent formats failed to inhibit this oseltamivir-re-
sistant virus (Table 2). These results also suggest that the epitope
recognized by N1-3-VHHm and N1-5-VHHm is conserved be-
tween the NAs of clade 1 and 2 H5N1 viruses.
Intranasal administration of a relatively high dose of N1-3-
VHHb or N1-5-VHHb (60 g; 3.3 mg/kg) 24 h before an H5N1
challenge protected mice against death, but significant body
weight was still lost (Fig. 5). In this challenge model, the N1-
VHH-Fc formats protected better than the N1-VHHb formats. A
single dose of 17 g (1.1 mg/kg, N1-3-VHH-Fc) or 3.5 g (0.23
mg/kg, N1-5-VHH-Fc) resulted in 100% survival of mice and less
morbidity than in control-treated animals (Fig. 6 and 7). When
comparing the molar ratios of N1-VHH-Fc (N1-3-VHH-Fc and
N1-5-VHH-Fc) with N1-VHHb (N1-3-VHHb or N1-5-VHHb),
we found that approximately 10 to 50 times smaller amounts of
the N1-VHH-Fc formats were necessary for 100% survival of
H5N1-challenged mice. For comparison, also in a mouse model,
conventional MAb 2B9 resulted in only partial (50%) protection
against an H5N1 A/Vietnam/1194/2004 challenge (74). Even so,
this required the intravenous administration of 500 g (33.3 mg/
kg) of 2B9 1 h before 10 LD50s of HPAIV H5N1, with daily boosts
for 5 days. Furthermore, when we compared the 2B9 treatment
with our single-dose treatment with N1-VHHb or N1-VHH-Fc, a
10- or 150-fold smaller amount of MAb, respectively, was re-
FIG 8 Epitope mapping on the NA of N1-5-VHHm escape NIBRG-14ma mutants. MDCK cells were infected with NIBRG-14ma in the presence of 3.7 M
N1-5-VHHm. Evidence of resistant viruses was based on a cytopathic effect on infected cell cultures and was monitored by plaque purification of candidate
escape viruses. The NA coding sequence of the resultant escape viruses was amplified by RT-PCR and sequenced. One selected escape virus carried an Ile-to-Thr
change at position 437. The deduced amino acid sequence in NA was modeled with PyMol (Delano Scientific, http://www.pymol.org) with the H5N1 NA
structure derived from A/Vietnam/1194/2004 (PDB code 2HTY). (A) Top (left) and lateral (right) views of the surface-exposed amino acid residues of the NA
dimer. The I437T amino acid substitution of the NA of the N1-5-VHHm escape mutant is surface exposed and marked in yellow. Residues that form the
catalytic-site framework are depicted in red. The N1 “150 loop” is shown in green. For comparison, the residues involved in MAb HCA-2 binding are shown in
dark blue (residues 222 to 230) and those involved in MAb 3H10 binding are shown in orange (N272, V339, and S340). (B) Sequence alignment of relevant N1
NAs. The I437T change in one of the N1-5-VHHm escape viruses is highlighted in yellow. The residues highlighted in red are important forMAb 3H10 binding.
(C) Fluorogram showing the T-to-C substitution in the cloned cDNA of the N1-5-VHHm escape virus (left). Mono- and bivalent NA-specific VHHs bind to
NIBRG-14 virus but not to I437T escape virus (right). ELISA plates were coated with 8 HA units of NIBRG-14 or I437T virus and, after blocking, incubated with
different concentrations of N1-3-VHHm, N1-3-VHHb, N1-5-VHHm, or N1-5-VHHb. N1-VHH binding was revealed with an anti-His tag MAb.
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quired to rescue 100% of the H5N1-challenged mice without any
boost. Compared with a study byWan et al., the smallest prophy-
lactic single dose of a conventional IgG2a MAb necessary to fully
rescue mice from a 10-LD50 H5N1 challenge was 15 mg/kg,
whereas 0.23mg/kg of ourN1-5-VHH-Fc protected all of themice
from death after a 4-LD50 challenge with NIBRG-14ma (67). The
target NA of NIBRG-14 (derived from A/Vietnam/1194/2004) is
almost identical to that used in the Wan study (A/Vietnam/1203/
2004). In both of the reports on NA MAbs discussed above (67,
74), the route of administration (intravenous or intraperitoneal)
could have been an important factor and it might help explain the
apparent superior protection of our N1-VHH formats, which we
administered intranasally, since VHHs withstand nebulization.
Moreover, it has been shown that anti-RSV Nanobodies give ex-
tended protection against viral infection in vivo when adminis-
tered via a nebulizer. It may be expected that optimization of its
delivery will further improve the efficacy of N1-VHH.N1-VHHm
treatments did not significantly reduce the virus titers or viral
genomic loads in lung homogenates 4 days after infection (Fig.
4C). The weak, direct antiviral activity of our NA-specific VHHs
in the in vivo model is in line with the paradigm that NA Abs or
NA-inhibitory drugs do not prevent infection.
The observation that N1-5-VHHm, N1-5-VHHb, and N1-5-
VHH-Fc did not have any antiviral activity against the oseltami-
vir-resistantH5N1H274Y virus in vitrowas surprising since in the
SPR assay, N1-3-VHHm andN1-5-VHHmbound to overlapping
epitopes in NA or sterically hindered each other’s binding (Fig.
1F). This discrepancy was also observed in vitro for N1-7-VHHm,
whereas N1-7-VHH-Fc did protect mice against a challenge with
the H5N1 H274Y mutant virus (Fig. 7). The latter observation
indicates that protection by NA-based Abs does not require the
NAI activity of these Abs, provided that an Fc domain is present to
contribute Fc receptor-dependent effector functions. The finding
that N1-7-VHH-Fc also had in vivo antiviral activity despite a lack
of NAI activity is in line with this (Fig. 7B and D). Mouse IgG2a is
one of the most potent Ab isotypes to induce Ab-dependent cel-
lular cytotoxicity or complement-dependent cellular cytotoxicity,
because of its high affinity for Fc
RIII and -IV and especially for
Fc
RI, which binds exclusively to IgG2a. IgG2a has an intermedi-
ate affinity for Fc
RIV that is 1 order of magnitude higher than its
affinity for the inhibitor receptor Fc
RIIB (75).
VHH CDR3 is a major region responsible for the contact of
VHH with antigen (25, 76). All of the NA-inhibitory N1-VHHs
reported here (N1-1-VHHm, N1-3-VHHm, N1-5-VHHm, and
N1-6-VHHm) have a predicted electronegatively charged pro-
truding paratope that corresponds to their CDR3 (Fig. 1C andD).
The CDR3 sequences of N1-3-VHHm (HGXXHGHGXHX, 10
residues) and N1-5-VHHm (HXHXHHXHXH, 12 residues),
where H is a hydrophobic residue and X is an aspartic or glutamic
acid, might be involved in the direct contact with their epitope or
epitopes. When comparing N1-3-VHHm and N1-5-VHHm
CDR3 sequences with the most potent NA-inhibitory VHHs re-
ported by Harmsen et al., we found similarities in their CDR3
sequences. For example, the CDR3 sequences of one N8-binding
VHH(UHXHHHGHGUHHXUPHXH, 18 residues) and oneN2-
binding VHH (HHXHGHHGGHGHUHXH, 16 residues), where
U is a polar uncharged residue, showed similarities to the N1-3-
VHHm and N1-5-VHHm CDR3s.
The available crystal structures of MAbs in complex with NA
are all for the group 2 NA, specifically, N2 and N9 (77–80). These
structures showed that these MAb epitopes rarely include con-
served amino acid residues from the catalytic site; rather, they
target amino acids in loops surrounding the NA catalytic site, also
described as the major antigenic regions of NA. It seems that the
N1-5-VHHm epitope is partially shared with other N1 NA mole-
cules, as the pandemic H1N1 NAI suggests (Fig. 3).
Plant-produced Abs have been considered a promising and
effective alternative for Ab production by recombinant yeast or
mammalian cell culture systems. Our N1-VHH-Fc is the first re-
ported plant-produced Ab against an influenza virus antigen.
Their scalability, robustness, and speed of production are major
advantages, even though the glycosylation patterns of the plant-
produced Abs (rich in high-mannose residues) are different from
those of the Abs produced with mammalian expression platforms
(81). The use of plants for Ab production also presents an inter-
esting approach for developing countries; long storage life, rela-
tive ease of purification or delivery, and the use of established
agricultural techniques are very attractive. To our knowledge,
only three single-domain Abs produced in plants have been re-
ported as stably transformed lines (82–84), but their yields were
very low. Results from our lab demonstrated that the Fc moiety
significantly improved VHH accumulation in seeds (compared to
themonomeric VHHalone)with expression levels of 10 to 20%of
the total seed proteins (54, 85).
HPAIV H5N1 remains a public health threat. The experimen-
tal adaptation of H5N1 virus for airborne transmission in ferrets,
withmutations inHA and PB2, warns of the possibility of human-
to-human transmission of zoonotic HPAIV (1, 2). ShouldHPAIV
H5N1 become transmissible among humans, NA targeting could
be part of an effective strategy to mitigate disease caused by such a
virus. In addition, an interesting prophylactic and therapeutic ap-
proach that deserves further validation is the combination of
VHH-targeting IAV NA, HA, or M2 proteins in cocktails or bipa-
ratopic bivalent VHH constructs that could diminish the anti-
genic drift in IAV and lead to much higher selective pressure
against IAV VHH.
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